You have 0 items in your cart
The next generation of obesity medicines is moving beyond GLP-1 alone.
One of the most interesting new candidates is eloralintide, an investigational once-weekly selective amylin receptor agonist being developed by Eli Lilly.
Eloralintide is being studied both on its own and in combination with tirzepatide.
That combination, known as EloraTZP, has already produced striking Phase 2b results and is moving toward Phase 3 development. (Eli Lilly and Company)
What Is Eloralintide?
Eloralintide, previously known as LY3841136, is an investigational injectable medicine designed to activate the amylin pathway.
It is intended for once-weekly administration.
Unlike GLP-1 receptor agonists, eloralintide is designed to preferentially activate the AMY1 receptor, one of the receptors involved in amylin signalling. (Lilly)
This makes it a different type of metabolic treatment from semaglutide or tirzepatide.
What Is Amylin?
Amylin is a hormone naturally released by pancreatic beta cells after eating.
It is secreted alongside insulin and helps regulate:
- appetite
- satiety
- food intake
- gastric emptying
- post-meal glucose handling
In simple terms, amylin contributes to the feeling of fullness that develops after eating.
Researchers are increasingly interested in whether this pathway can be targeted therapeutically for obesity.
How Is Eloralintide Different From GLP-1 Drugs?
GLP-1 medicines act primarily through the GLP-1 receptor.
Eloralintide acts through the amylin receptor system.
Both pathways can influence appetite and satiety, but they do so through different biological mechanisms.
This means eloralintide may provide another way of reducing calorie intake without simply reproducing the mechanism of existing GLP-1 medicines.
That distinction is one reason amylin research has become such a major area of interest.
Why Is Eloralintide Selective?
Natural amylin interacts with several receptor combinations.
Eloralintide has been engineered to preferentially activate AMY1R.
Researchers hope that greater receptor selectivity may allow them to preserve useful metabolic effects while potentially producing a different tolerability profile from broader amylin analogues.
Whether that translates into meaningful clinical advantages is still being established.
What Have the Clinical Trials Shown?
Eloralintide has completed Phase 1 and Phase 2 studies and is now being investigated in several Phase 3 trials.
Lilly’s ENLIGHTEN programme includes studies in people with obesity or overweight:
- without type 2 diabetes
- with type 2 diabetes
- with obstructive sleep apnoea
- with osteoarthritis-related knee pain
A separate Phase 3 study is also examining eloralintide as an add-on treatment in people already receiving an incretin-based medicine. (Lilly)
What Is ENLIGHTEN-1?
ENLIGHTEN-1 is a Phase 3 trial studying eloralintide in adults with obesity or overweight who do not have type 2 diabetes.
The trial plans to enrol around 1,980 participants and began in 2026. (Lilly Trials)
This is one of the key studies that should establish how effective eloralintide is as a standalone obesity treatment.
What Is ENLIGHTEN-2?
ENLIGHTEN-2 is another Phase 3 study.
This trial is investigating eloralintide in adults with obesity or overweight who also have type 2 diabetes.
The study plans to enrol approximately 1,035 participants. (Lilly Trials)
Together, ENLIGHTEN-1 and ENLIGHTEN-2 will provide much stronger evidence than the earlier Phase 2 programme.
What Is EloraTZP?
EloraTZP is the name Lilly is using for the combination of:
eloralintide
plus
tirzepatide
Tirzepatide already activates both GIP and GLP-1 receptors.
Adding eloralintide introduces a third pathway: amylin.
EloraTZP can therefore be described as a triple-pathway metabolic strategy involving:
- amylin
- GIP
- GLP-1
The idea is to combine complementary appetite and metabolic signals rather than relying on a single hormone system. (Eli Lilly and Company)
What Did the EloraTZP Phase 2b Trial Show?
In September 2026, Lilly announced results from a 48-week Phase 2b trial involving 367 adults with obesity or overweight and type 2 diabetes.
Participants received placebo, eloralintide, tirzepatide or different combinations of eloralintide and tirzepatide.
The strongest EloraTZP combination produced average weight loss of up to approximately 23.3%, compared with around 14.8% with tirzepatide 15 mg alone.
A1C reductions also reached up to approximately 2.9 percentage points, compared with around 2.4 percentage points with tirzepatide alone. (Eli Lilly and Company)
These results are particularly notable because tirzepatide is already a highly effective metabolic therapy.
Does This Mean EloraTZP Is Better Than Tirzepatide?
The Phase 2b results suggest that combining the pathways may produce greater average weight reduction in the studied population.
But one Phase 2b trial is not enough to establish that the combination is universally superior.
Researchers still need to determine:
- long-term safety
- optimal dosing
- gastrointestinal tolerability
- treatment discontinuation rates
- effects in people without diabetes
- cardiovascular outcomes
- body-composition changes
Phase 3 trials will provide much stronger evidence.
Is EloraTZP Moving Into Phase 3?
Yes.
Lilly announced that it plans to begin the AMPLIFY Phase 3 programme for the co-formulated EloraTZP product by the end of 2026. (Eli Lilly and Company)
The programme is expected to compare the combination with tirzepatide and eloralintide alone across different populations.
This makes EloraTZP one of the more important next-generation obesity programmes currently entering late-stage development.
Can Eloralintide Be Added to Existing Incretin Treatment?
Researchers are studying exactly that.
The ENLIGHTEN-6 Phase 3 trial is investigating eloralintide in people with persistent obesity or overweight who are already receiving a stable weekly incretin therapy.
Around 900 participants are expected to enrol. (Lilly Trials)
This is potentially important because future obesity treatment may increasingly involve adding a second mechanism when weight loss plateaus on an existing drug.
Is Eloralintide Being Combined With Other Experimental Drugs?
Yes.
Lilly is also studying eloralintide with macupatide, another experimental metabolic compound.
A Phase 2 programme is evaluating the drugs alone and in combination in adults with obesity or overweight. (Lilly Trials)
This reflects a broader shift toward combination metabolic therapies.
Eloralintide vs Petrelintide
Eloralintide and petrelintide are both part of the growing amylin field.
But they are not identical compounds.
Petrelintide is a long-acting amylin analogue.
Eloralintide is a selective amylin receptor agonist designed to preferentially activate AMY1R.
Both are being developed as once-weekly therapies.
Both have now entered late-stage clinical research.
The next several years should provide much clearer evidence about whether selective receptor targeting or broader amylin mimicry offers the best balance of effectiveness and tolerability.
Why Are Researchers So Interested in Amylin?
GLP-1 has demonstrated that appetite-regulating hormone pathways can produce substantial changes in body weight.
Researchers are now looking for additional pathways that can either:
- provide alternatives to GLP-1
- improve tolerability
- produce additional weight reduction
- help people who plateau on existing therapies
- work synergistically with incretin drugs
Amylin is one of the strongest candidates.
Is Eloralintide a Peptide?
Yes.
Eloralintide is a peptide-based amylin receptor agonist.
It therefore fits naturally within emerging peptide therapeutics research.
Its biological target is distinct from the better-known GLP-1 and GIP pathways.
Is Eloralintide Approved?
No.
Eloralintide remains investigational.
It has not yet been approved for routine clinical use.
Its Phase 3 programme is ongoing, and the final balance between effectiveness, safety and tolerability has not yet been established. (Lilly)
Why Is Eloralintide Important?
Eloralintide represents an important change in the direction of obesity research.
Rather than trying to create another GLP-1 agonist, researchers are increasingly combining different hormonal signals that regulate eating and metabolism.
Eloralintide may eventually be used:
- as a standalone amylin-based treatment
- as an add-on to existing incretin therapy
- or as part of a combined amylin/GIP/GLP-1 treatment
Which of those strategies proves most useful remains uncertain.
The Bottom Line
Eloralintide is an investigational once-weekly selective amylin receptor agonist currently in Phase 3 clinical development for obesity and related metabolic conditions. (Lilly)
It is also being combined with tirzepatide to create EloraTZP, a treatment strategy targeting amylin, GIP and GLP-1 simultaneously.
In a 48-week Phase 2b trial involving adults with obesity or overweight and type 2 diabetes, the strongest EloraTZP regimen produced average weight loss of up to approximately 23.3%, compared with 14.8% with tirzepatide 15 mg alone. (Eli Lilly and Company)
Those are compelling early results.
But the combination remains experimental, and Phase 3 research will determine whether the additional effects are sustained and whether the safety and tolerability profile supports widespread clinical use.
For researchers following the evolution beyond GLP-1 therapies, eloralintide is one of the most important emerging peptides to watch.
This article is for research and educational purposes only. Eloralintide and EloraTZP remain investigational and are not presented as approved treatments.